Keytruda is administered via a 30 min intravenous (IV) infusion every 3-6 weeks. A response to treatment is typically seen within 2-4 months of starting treatment with Keytruda, but the time it takes to work will vary based on cancer type and the stage of disease.

KEYTRUDA is a prescription medicine used to treat a kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread, and tests positive for “PD-L1.”

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based ...

Keytruda is recommended in current treatment guidelines as a treatment option for triple-negative breast cancer in certain situations. In clinical studies Keytruda has been effective in treating this type of breast cancer.

According to clinical trials and studies, one of the most noticeable signs that Keytruda is working is tumor shrinkage.

A typical cycle of immunotherapy lasts two to three weeks, with most people undergoing several cycles. After your immunotherapy treatment, your body needs time to respond and develop a new fleet of cancer-fighting immune system cells. As a result, it often takes two months or more before you start to see results.

Pembrolizumab (pronounced pem-bro-lih-zoo-mab) is a type of immunotherapy. It is also known by its brand name, Keytruda. You might have it as a treatment by itself or in combination with another treatment for a number of different cancer types.

KEYTRUDA® (pembrolizumab) for Non–Small Cell Lung Cancer. Non–small cell lung cancer (NSCLC) CHANGE. Non–small cell lung cancer (NSCLC)CHANGE.

Keytruda is the first cancer immunotherapy to be approved in India for the treatment of cervical cancer and the first immunotherapy to be approved as a first-line treatment for a significant sub-group of patients, who otherwise only had the option of chemotherapy as their treatment for esophageal cancer.

KEYTRUDA® (pembrolizumab) for Non–Small Cell Lung Cancer. Non–small cell lung cancer (NSCLC) CHANGE. Non–small cell lung cancer (NSCLC)CHANGE.

Of the patients who completed approximately two years of treatment (35 cycles) with KEYTRUDA plus pemetrexed and cisplatin or carboplatin (n=57/405), 71.9% were alive at five years following randomization, with an ORR of 86.0% (with eight complete responses and 41 partial responses).

KEYTRUDA may help shrink tumors These results are from a clinical trial, which included 98 people with cervical cancer that had either spread or come back after chemotherapy, or when chemotherapy did not work or was no longer working.